GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...

GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal "bias." ...

GLP-1 receptor agonists lead a new wave of therapeutic options that may benefit patients with osteoarthritis, according to ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

Recently, tennis legend Serena Williams opened up about using weight-loss medication, aiming to break the ‘stigma’ around such treatments. The 43-year-old, who has won 23 Grand Slam titles and is the ...

HOUSTON -- Patients with polycythemia vera (PV) and a history of treatment with GLP-1 agonists had significantly lower rates of multiple adverse outcomes associated with the disease, a large ...

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug ...

"Type 2 diabetes in children and teens is increasing at an alarming rate, yet treatment options are limited, and this patient population remains underserved," said Kenneth Custer, Ph.D., executive ...

No significant association was observed between GLP-1 receptor agonists and an increased risk for suicide death, with an adjusted hazard ratio [aHR] of 1.25 (95% CI, 0.83-1.88). The aHR for the ...

GLP-1 drugs are expanding beyond diabetes to potentially reduce heart disease and improve sleep quality. Market for GLP-1 drugs is set to grow from $70 billion in 2025 to $157 billion by 2030, led by ...